glp-1 drugs pharmaceutical companies partnerships 2025 Drugs: Pulse Survey (U.S.) Designing GLP-1 delivery: structural perspectives

This does not disqualify the research material

doi: 10.1111/apt.16148 277 IaniroGMullishBHKellyCRKassamZKuijperEJNgSCet al

Glucose-dependent insulinotropic polypeptide signaling in pancreatic -cells and adipocytes

Mechanisms affecting BBB to neurodegeneration Neurodegenerative diseases such as AD, PD, ALS, and MS, while distinct in clinical presentation, share a convergence on impaired BBB stability, CBF reduction, and vascular inflammation, reflecting parallel paths of progressive neurodegeneration distinct from acute brain injuries

Here you can find some references and papers you can take to you GP regarding this